VOZMOZhNOSTI SOVREMENNOY TERAPII KhRONIChESKOGO PIELONEFRITA V USLOVIYaKh DNEVNOGO STATsIONARA
- Authors: Gracheva IL1, Kazakova IA1
-
Affiliations:
- Issue: No 1 (2011)
- Pages: 35-38
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/245936
- ID: 245936
Cite item
Full Text
Abstract
Aim. Assessment of nadroparin calcium clinical efficacy in treatment of chronic pyelonephritis in day patient facility.
Methods. 31 patients with primary recurrent chronic pyelonephritis an 33 patients with secondary chronic pyelonephritis, associated with arterial hypertension, in day patient facility received nadroparin calcium (0,3 ml/day) for 10 days. 20 patients primary recurrent chronic pyelonephritis an 22 patients with secondary chronic pyelonephritis received placebo. Proteinuria, estimated glomerulary filtration rate (eGFR), creatinemia and renoscintigraphy parameters were evaluated. β2-microglobulin and N-acetyl- β-D-gexoamindase urinary excretion were determined and ambulatory blood pressure monitoring was performed.
Results. Nadroparin calcium therapy was associated with more pronounced decrease of proteinuria, leucocyturia, and blood pressure, especially in patients with secondary chronic pyelonephritis. Period of hospitalization also decreased.
Conclusion. Nadroparin calcium should be included into therapeutic strategies, which are used in chronic pyelonephritis
Methods. 31 patients with primary recurrent chronic pyelonephritis an 33 patients with secondary chronic pyelonephritis, associated with arterial hypertension, in day patient facility received nadroparin calcium (0,3 ml/day) for 10 days. 20 patients primary recurrent chronic pyelonephritis an 22 patients with secondary chronic pyelonephritis received placebo. Proteinuria, estimated glomerulary filtration rate (eGFR), creatinemia and renoscintigraphy parameters were evaluated. β2-microglobulin and N-acetyl- β-D-gexoamindase urinary excretion were determined and ambulatory blood pressure monitoring was performed.
Results. Nadroparin calcium therapy was associated with more pronounced decrease of proteinuria, leucocyturia, and blood pressure, especially in patients with secondary chronic pyelonephritis. Period of hospitalization also decreased.
Conclusion. Nadroparin calcium should be included into therapeutic strategies, which are used in chronic pyelonephritis
References
- Лоран О.Б., Синякова Л.А., Берников Е.В., Охриц В.Е. Хронический пиелонефрит: особенности диагностики и лечения в амбулаторной практике. Consilium medicum 2009; 11(7): 5- 8.
- Борисов И.А. Пиелонефрит В: Тареева И.Е. (ред.) Нефрология: руководство для врачей. М.: Медицина. 2000. 383-399.
- Картамышева Н.Н., Чумакова О.В., Кучеренко А.Г. Факторы прогрессирования хронического пиелонефрита и хронического интерстициального нефрита. Педиатрия 2004; 5: 50-53.
- Кутырина И.М., Рогов В.А., Шестакова М.В., Зверев К.В. Гиперфильтрация как фактор прогрессирования хронических заболеваний почек. Терапевтический архив 1992; 6: 10-15.
- Лавиль М. Роль артериальной гипертонии в прогрессировании почечной недостаточности, эффективность антигипертензивной терапии. Нефрология 2000; 4 (1): 119-121.
- Смирнов А.В. Дислипопротеидемии и проблемы нефропротекции. Нефрология 2002; 6 (2): 8-14.
- Смирнов А.В. (ред.), Добронравов В.А., Каюков И.Г. и др. Рекомендации Научно-исследовательского института нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова: определение, классификация, диагностика и основные направления профилактики хронической болезни почек у взрослых. Пособие для врачей. Санкт-Петербург: Левша.Санкт-Петербург. 2008.
- Mazzy Z.A., Khoa T.N., Lcoure B., Jungers P. Dislipidemia and progression of renal disease in chronic renal failure patients. Nephrol. Dial. Transplant. 1999; 14: 2392-2397.
- Haroun N.K., Jaar B.G., Hoffman S.C. et al. Risk factors for chronic Kidney disease: a prospective study of 23.534 men and women in Washington Country, Maryland. J. Am. Soc. Nephrol. 2003; 14: 2934-2941.
- Jafar T.N., Stark P.C., Schmid C.N. et al. Progression of chronic kidney diasease: the role of blood pressure control, proteinuria and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann. Intern. Med. 2003; 139(4): 244-252.
- Levey A.S., Eckardt K.U., Tsukamoto Y. et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcome (KDIGO). Kidney Int. 2005; 67 (6): 2089-2100.
- National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney. Dis. 2002; 39 (1): 1-266.
- Ruelope Z.M., Salvetti A., Jamerson K. et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J. Am. Soc. Nephrol. 2001; 12: 218-225.
- Schaeffner E.S., Kurth T., Curhan G.C. et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J. Am. Soc. Nephrol. 2003; 14: 2084-2091.
- Моисеев В.С. Низкомолекулярные гепарины. Клиническая фармакология и терапия 1999; 1: 72-79.
- Староверов И.И. Низкомолекулярные гепарины. АтмосферА. Кардиология 2005; 1: 8-10.
- Дедов И.И., Шестакова М.В. Диабетическая нефропатия. Москва, Универсум Паблишинг. 2000.
- Козловская Н.Л., Бобкова И.Н., Тареева И.Е., Пономарева И.К. Применение низкомолекулярного гепарина эноксапарина в лечении больных хроническим гломерулонефритом. Клиническая фармакология и терапия 2001; 10: 47-49.
- Козловская Н.Л., Шахнова Е.А., Кушнир В.В., Шилов Е.М. Низкомолекулярные гепарины в лечении АФС-нефропатии при первичном и вторичном антифосфолипидном синдроме. Терапевтический архив 2004; 9: 35-40.
Supplementary files
